ATE502631T1 - Verbindungen zur behandlung von stoffwechselstörungen - Google Patents

Verbindungen zur behandlung von stoffwechselstörungen

Info

Publication number
ATE502631T1
ATE502631T1 AT04781277T AT04781277T ATE502631T1 AT E502631 T1 ATE502631 T1 AT E502631T1 AT 04781277 T AT04781277 T AT 04781277T AT 04781277 T AT04781277 T AT 04781277T AT E502631 T1 ATE502631 T1 AT E502631T1
Authority
AT
Austria
Prior art keywords
compounds
treatment
metabolic disorders
agent
metabolic
Prior art date
Application number
AT04781277T
Other languages
English (en)
Inventor
Shalini Sharma
Borstel Reid Von
Kirvin Hodge
Original Assignee
Wellstat Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp
Application granted granted Critical
Publication of ATE502631T1 publication Critical patent/ATE502631T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT04781277T 2003-08-20 2004-08-16 Verbindungen zur behandlung von stoffwechselstörungen ATE502631T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49653303P 2003-08-20 2003-08-20
PCT/US2004/026561 WO2005018628A1 (en) 2003-08-20 2004-08-16 Compounds for the treatment of metabolic disorders

Publications (1)

Publication Number Publication Date
ATE502631T1 true ATE502631T1 (de) 2011-04-15

Family

ID=34216015

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04781277T ATE502631T1 (de) 2003-08-20 2004-08-16 Verbindungen zur behandlung von stoffwechselstörungen

Country Status (18)

Country Link
US (1) US7906675B2 (de)
EP (1) EP1656127B1 (de)
JP (1) JP4703563B2 (de)
KR (1) KR101069276B1 (de)
CN (2) CN101948416A (de)
AT (1) ATE502631T1 (de)
AU (1) AU2004266673B2 (de)
BR (1) BRPI0413758A (de)
CA (1) CA2533890A1 (de)
DE (1) DE602004031954D1 (de)
IL (1) IL173377A (de)
MX (1) MXPA06001963A (de)
NO (1) NO20060502L (de)
NZ (1) NZ545268A (de)
RU (1) RU2349584C2 (de)
UA (1) UA88772C2 (de)
WO (1) WO2005018628A1 (de)
ZA (1) ZA200600577B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2530235T3 (es) * 2003-02-13 2015-02-27 Wellstat Therapeutics Corporation Compuestos para el tratamiento de trastornos metabólicos
ES2353601T3 (es) * 2003-04-15 2011-03-03 Wellstat Therapeutics Corporation Compuestos para el tratamiento de trastornos metabólicos.
CA2522738C (en) * 2003-04-30 2011-11-08 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2006127133A2 (en) * 2005-04-01 2006-11-30 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
UA95613C2 (ru) * 2005-11-09 2011-08-25 Уеллстат Терепьютикс Корпорейшн Соединения для лечения расстройсв метаболизма
US7820721B2 (en) * 2006-01-25 2010-10-26 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP1976510A4 (de) * 2006-01-25 2010-06-09 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen
AU2007208127A1 (en) * 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
JP2009525982A (ja) * 2006-02-02 2009-07-16 ウェルスタット セラピューティクス コーポレイション 代謝障害の治療のための化合物
EP1983972A4 (de) * 2006-02-13 2012-01-25 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen
KR20080098615A (ko) * 2006-02-28 2008-11-11 웰스태트 테러퓨틱스 코포레이션 물질대사 장애의 치료용 화합물
WO2007117791A2 (en) * 2006-03-31 2007-10-18 Wellstat Therapeutics Corporation Combination treatment of metabolic disorders
CA2651598A1 (en) * 2006-05-18 2007-11-29 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US20100234464A1 (en) * 2006-06-09 2010-09-16 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2009091732A1 (en) * 2008-01-15 2009-07-23 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
CN109096350B (zh) * 2017-09-21 2020-07-28 暨南大学 辣木籽中新的硫醚类化合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE667498A (de) 1964-07-28 1965-11-16
CN1315473C (zh) * 1997-03-17 2007-05-16 英国技术集团国际有限公司 治疗组合物
RU2341513C2 (ru) * 2001-06-12 2008-12-20 Веллстат Терапьютикс Корпорейшн Соединения для лечения метаболических заболеваний
CA2502297C (en) * 2002-11-01 2011-12-13 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
ES2530235T3 (es) * 2003-02-13 2015-02-27 Wellstat Therapeutics Corporation Compuestos para el tratamiento de trastornos metabólicos
ES2353601T3 (es) * 2003-04-15 2011-03-03 Wellstat Therapeutics Corporation Compuestos para el tratamiento de trastornos metabólicos.
CN1777576A (zh) * 2003-04-22 2006-05-24 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
CA2522738C (en) * 2003-04-30 2011-11-08 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders

Also Published As

Publication number Publication date
NZ545268A (en) 2009-05-31
JP2007502824A (ja) 2007-02-15
US20070282003A1 (en) 2007-12-06
CA2533890A1 (en) 2005-03-03
KR20060066730A (ko) 2006-06-16
CN101948416A (zh) 2011-01-19
AU2004266673B2 (en) 2010-08-05
IL173377A (en) 2012-12-31
BRPI0413758A (pt) 2006-10-31
RU2349584C2 (ru) 2009-03-20
MXPA06001963A (es) 2006-05-31
EP1656127B1 (de) 2011-03-23
HK1087040A1 (en) 2006-10-06
CN1835743A (zh) 2006-09-20
US7906675B2 (en) 2011-03-15
EP1656127A4 (de) 2009-04-29
DE602004031954D1 (de) 2011-05-05
WO2005018628A1 (en) 2005-03-03
RU2006108572A (ru) 2006-07-27
JP4703563B2 (ja) 2011-06-15
UA88772C2 (ru) 2009-11-25
ZA200600577B (en) 2007-01-31
NO20060502L (no) 2006-05-03
IL173377A0 (en) 2006-06-11
AU2004266673A1 (en) 2005-03-03
EP1656127A1 (de) 2006-05-17
KR101069276B1 (ko) 2011-10-04

Similar Documents

Publication Publication Date Title
ATE402180T1 (de) Verbindungen zur behandlung von dyslipidemie
DE602004031954D1 (de) Verbindungen zur behandlung von stoffwechselstörungen
ATE368031T1 (de) Neue gamma secretase inhibitoren
NO20071719L (no) Pyridylinhibitorer for "hedgehog"-signalisering
NO20070606L (no) Inhibitorer av IAP
ATE525067T1 (de) Amino-substituierte (e)-2,6-dialkoxystyryl 4- substituierte benzylsulfone zur behandlung von proliferierenden erkrankungen
TW200510317A (en) Caspase inhibitors and uses thereof
ATE373474T1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
NO20052787D0 (no) N-alkyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
ATE433447T1 (de) Pyrimiidinverbindungen
ATE386030T1 (de) 1,4-disubstituierte benzokondensierte cycloalkyl- harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
ATE338461T1 (de) Pyrazolpyrimidinfungizide
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
ATE420639T1 (de) Antimykotische mittel
DE602005009209D1 (de) Zur behandlung von entzündungen geeignete indole
DE60220385D1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
ATE429909T1 (de) Nützliche verbindungen für die behandlung von anthrax und hemmung des letalen faktors
SE0101082D0 (sv) Novel use
NO331012B1 (no) N-sulfonyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
ATE539756T1 (de) Prostaglandinsubstanzen für die behandlung von fettsucht
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties